Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.71 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.53 |
| ▸ | PIM1 | P11309 | 3/20 | 0.52 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.52 |
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1291462 | 1.00 | GPR119 (0.71) | GPR119AKR1B1PIM1PIM2ADAMTS5 | |
| SCHEMBL1291495 | 1.00 | GPR119 (0.71) | GPR119AKR1B1PIM1PIM2ADAMTS5 | |
| SCHEMBL1291506 | 0.91 | GPR119 (0.71) | GPR119AKR1B1PIM1PIM2 | |
| SCHEMBL15260501 | 0.87 | GPR119 (0.72) | GPR119AKR1B1PIM1PIM2ADAMTS5 | |
| SCHEMBL1291620 | 0.87 | GPR119 (0.72) | GPR119AKR1B1PIM1PIM2ADAMTS5 | |
| SCHEMBL1291618 | 0.87 | GPR119 (0.72) | GPR119AKR1B1PIM1PIM2ADAMTS5 | |
| SCHEMBL12469608 | 0.87 | GPR119 (0.59) | GPR119AKR1B1PIM1PIM2ADAMTS5 | |
| SCHEMBL1292032 | 0.87 | GPR119 (0.72) | GPR119AKR1B1PIM1PIM2ADAMTS5 | |
| SCHEMBL1291666 | 0.87 | GPR119 (0.72) | GPR119AKR1B1PIM1PIM2ADAMTS5 | |
| SCHEMBL1291435 | 0.87 | GPR119 (0.82) | GPR119AKR1B1PIM1PIM2ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2625177-B1 | NOVEL GPR 119 AGONISTS | CADILA HEALTHCARE LTD (IN) | 2015-07-29 | — | — | EP | disclosed |
| US-8785463-B2 | GPR 119 agonists | CADILA HEALTHCARE LIMITED (IN) | 2014-07-22 | — | — | US | disclosed |
| US-20130252980-A1 | NOVEL GPR 119 AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2013-09-26 | — | — | US | disclosed |
| EP-2625177-A1 | NOVEL GPR 119 AGONISTS | Cadila Healthcare Limited (IN) | 2013-08-14 | — | — | EP | disclosed |
| WO-2012046249-A1 | NOVEL GPR 119 AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252980-A1 | NOVEL GPR 119 AGONISTS | GPR119, GPR27, GPR4 | GPR119 1/4885AKR1B1 691/4885PIM1 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.